FDA Accepts NDA Review for T-3811, Quinolone Antibiotic Co-developed by Toyama Chemical and Schering-Plough.Tokyo, Japan, Feb 14, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Toyama Chemical announced on February 13 that it has received a notification on a drug candidate T-3811 from Schering-Plough. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the notification, the US Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) has accepted to review a New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for T-3811. Discovered by Toyama Chemical, T-3811 is a new type of broad-spectrum quinolone antibiotic for treating Gram-positive and Gram-negative bacterial infections. Toyama Chemical and Schering-Plough entered into a worldwide licensing agreement for T-3811 in June 2004. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion